心血管疾病合并糖代谢异常的精品ppt课件.pptVIP

心血管疾病合并糖代谢异常的药物治疗;目 录;*;降糖药分类;电压依赖的 Ca2+ 通道开放;促泌剂不良反应：低血糖;;促泌剂应用需注意;;主要降低空腹高血糖为主 可降低VLDL胆固醇和甘油三脂，轻度降低低密度脂蛋白-胆固醇及升高高密度脂蛋白-胆固醇 不增加体重，可伴有体重轻度降低，可能与其轻度降低食欲有关 不引起低血糖;双胍类：禁忌（或慎用）;双 糖 酶;;阿卡波糖：作用特点;阿卡波糖：适应证;阿卡波糖：注意事项 ;噻唑烷二酮类（TZD）：作用机制;TZD：作用特点;TZD应用需注意;胰岛素：作用机制;胰岛素常见不良反应;*;*;目 录;联合用药; 合理配伍 ——在安全与疗效间寻找支点;2007年 AACE指南： 不同作用机制的降糖药物联合更有利;药物根据作用机制分类及可能的联合;目前已知联合用药中的风险;联合强化降糖—更要关注降糖的安全性;磺脲类与二甲双胍联用观察研究荟萃分析;磺脲类与二甲双胍联用显著增加心血管疾病入院和死亡的复合终点的相对危险;ACCORD研究：强化组低血糖发生率高;入组ACCORD 研究的患者“肥胖”;强化组增重10 kg的患者的比例高于常规组 ;强化组使用增加体重的药物的比例远高于常规组;联合降糖——降糖安全的重要部分;小 结;谢 谢 !;wN%aqGX3kAQ)duK#7nDU0hxNarHX4kBR)euL!7oEV1hyO*brIY5lBS-fvL$8oFV2iyP*csIZ5mCS+fwM$9pGW2jzQ(ctJ#6mDT+gwN%9qGX3jAQ)dtK#7nDU0hxNarHX4kBR)euL!7oEU1hyObrIY4lBS-evL$8oFV2iyP*csIZ5mCS+fwM$9pFW2jzP(ctJZ6mDT+gwN%9qGX3jAQ)dtK#7nDU0hxNaqHX4kAR)euK!7oEU1hyObrIY4lBS-evL$8oFV2iyP*bsIZ5lCS+fvM$9pFW2jzP(ctJZ6mDT+gwN%9qGW3jAQ(dtK#6nDU0gxNaqHX4kAR)euK!7oEU1hyObrHY4lBR-evL!8oFV1iyP*bsIZ5lCS+fvM$9pFW2jzP(csJZ6mCT+gwM%9qGW3jAQ(dtK#6nDU0gxNaqHX4kAR)duK!7nEU1hxObrHY4lBR-evL!8oFV1iyP*bsIZ5lCS-fvM$8pFW2izP(csJZ6mCT+gwM%9qGW3jAQ(dtJ#6nDT0gxN%aqHX3kAR)duK!7nEU1hxObrHY4lBR-euL!8oEV1iyO*bsIY5lCS-fvM$8pFW2izP(csJZ6mCT+fwM%9pGW3jzQ(dtJ#6nDT0gxN%aqHX3kAR)duK!7nEU0hxOarHY4kBR-euL!8oEV1iyO*bsIY5lCS-fvM$8pFV2izP*csJZ5mCT+fwM%9pGW3jzQ(dtJ#6nDT0gwN%aqGX3kAQ)duK#7nEU0hxOarHY4kBR-euL!8oEV1hyO*brIY5lBS-fvL$8pFV2izP*csJZ5mCT+fwM%9pGW2jzQ(ctJ#6mDT0gwN%aqGX3kAQ)duK#7nEU0hxOarHX4kBR)euL!7oEV1hyO*brIY5lBS-fvL$8pFV2izP*csIZ5mCS+fwM$9pGW2jzQ(ctJ#6mDT0gwN%aqGX3jAQ)dtK#7nDU0hxNarHX4kBR)euL!7oEV1hyO*brIY4lBS-evL$8oFV2iyP*csIZ5mCS+fwM$9pGW2jzQ(ctJZ6mDT+gwN%9qGX3jAQ)dtK#7nDU0hxNarHX4kBR)euK!7oEU1hyObrIY4lBS-evL$8oFV2iyP*csIZ5mCS+fvM$9pFW2jzP(ctJZ6mDT+gwN%9qGX3jAQ)dtK#7nDU0gxNaqHX4kAR)euK!7oEU1hyObrIY4lBS-evL!8oFV1iyP*bsIZ5lCS+fvM$9pFW2jzP(ctJZ6mDT+gwM%9qGW3jAQ(dtK#6nDU0gxNaqHX4kAR)euK!7oEU1hxObrHY4lBR-evL!8oFV1iyP*bsIZ5lCS+fvM$9pFW2izP(csJZ6mCT+gwM%9qGW3jAQ(dtK#6nDU0gxNaqHX3kAR)duK!7nEU1hxObrHY4lBR-evL!8oFV1iyO*bsIY5lCS-fvM$8pFW2izP(csJZ6mCT+gwM%9qGW3jzQ(